Global Solid Tumor Testing Market - 1-3 USERS:2021

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2030 - Start Value : $22,504.1 Million in 2020 - Forecast Value : $40,660.6 Million by 2030 - CAGR % : 0.06%
Description :
Market Report Coverage - Solid Tumor TestingMarket Segmentation• Cancer-Prostate, Breast, Colorectal, Endometrial, Lung, Melanoma, Brain, Thyroid, Liver, Ovarian and Other• Application – Clinical and Research• End User – Academic and Research Institutions, Biopharmaceutical and Biotechnological Companies, Contract Research Organizations, and Other End UsersRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe• Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)• Latin America – Brazil, Mexico, and Rest-of-the-Latin America• Rest-of-the-WorldGrowth Drivers• Rising Incidence of Cancers• Decreasing Cost of Sequencing• Expected Increase in Adoption of Genetic Testing• Increasing Adoption of Inorganic Growth StrategiesMarket Challenges• Uncertain Reimbursement Policies• Requirement of High Capital Investment Hindering Expansion• High Pricing PressureMarket Opportunities• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations• Increasing Disposable Income in Emerging Companies• Technological Advancements in the Field of Cancer Genomics• Mushrooming Direct-to-Consumer Testing Services MarketKey Companies ProfiledAbbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant HealthKey Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global solid tumor testing market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period 2020-2030? Following are the segments: o cancer type o technology o application o end user o region • Which are the leading players with significant offerings to the global solid tumor testing market? • What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?Market OverviewBIS Research healthcare experts have found the solid tumor testing market to be one of the growing markets, which is predicted to grow at a CAGR of 6.09% during the forecast period, 2020-2030. The market is driven by the need for the development of an advanced solution based on various technologies such as next-generation sequencing, in-situ hybridization, and polymerase chain reaction for cancer research in various applications such as diagnosis, prognosis, and treatment.The market is favored by the development of high-throughput, rapid, sensitive, and multi-parametric solutions for prognosis, diagnostics, and treatment. The gradual increase in the prevalence of cancer globally has furthered the solid tumor testing market.Furthermore, several contract research organizations are focusing on the development of solid tumor testing services, which enable to perform an extensive preclinical study at lower operation costs and less turn-around time.Within the research report, the market is segmented on the basis of cancer type, technology application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, companies such as Quest Diagnostics Incorporated have been a pioneer and a significant competitor in this market.Other key players in the market are Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.On the basis of region, North America holds the largest share of the global solid tumor testing market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region.The global solid tumor testing market utilizes technologies such as next-generation sequencing, in-situ hybridization, immunohistochemistry, polymerase chain reaction, and other technologies for the development of advanced diagnostic tools to cater to a holistic approach toward the treatment of cancer. The rising incidence of cancer and the increasing global burden of the disease has subsequently furthered the growth of the market.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Rest-of-EuropeAsia-Pacific China India Australia Japan Singapore Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin AmericaRest-of-World
Keywords :
Solid Tumor Testing, Solid Tumor Testing Market, Solid Tumor Testing Industry, Solid Tumor Testing Report, Solid Tumor Testing Market Forecasts, Solid Tumor Testing Market Trends, Solid Tumor Testing Market Products, Solid Tumor Testing Market Applications, Solid Tumor Testing Market Companies, Solid Tumor Testing Market Analysis, Solid Tumor Testing Industry Analysis, What is Solid Tumor Testing, Solid Tumor Testing Definition, Solid Tumor Testing Market by Technology, Solid Tumor Testing Market by Cancer Type, Solid Tumor Testing Market by Application, Solid Tumor Testing Market by Region, Solid Tumor Testing Market by End User, Next-Generation Sequencing Solid Tumor Testing Market, In Situ Hybridization Solid Tumor Testing Market, Polymerase Chain Reaction Solid Tumor Testing Market, Immunohistochemistry Solid Tumor Testing Market, Breast Cancer Solid Tumor Testing Market, Prostate Cancer Solid Tumor Testing Market, Colorectal Cancer Solid Tumor Testing Market, Lung Cancer Solid Tumor Testing Market, Melanoma Solid Tumor Testing Market, Endometrial Cancer Solid Tumor Testing Market, Thyroid Cancer Solid Tumor Testing Market, Brain Cancer Solid Tumor Testing Market, Ovarian Cancer Solid Tumor Testing Market, Liver Cancer Solid Tumor Testing Market, Clinical Solid Tumor Testing Market, Research Solid Tumor Testing Market, North America Solid Tumor Testing Market, Europe Solid Tumor Testing Market, Asia-Pacific Solid Tumor Testing Market, Latin America Solid Tumor Testing Market
Press Release :
The premium market intelligence report published by BIS Research on the title Global Solid Tumor Testing Market highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030. The growth of the market is aided by rising government initiatives for the implementation of precision medicine coupled with the increasing incidence of cancers globally.Solid tumors are defined as abnormal cellular growth in various organs, referred to as sarcomas, carcinomas, and lymphomas. The global cancer burden has been growing exponentially, specifically in countries with medium and low health development indexes. In 2020, breast cancer had the highest incidence of 2.3 million new cancer cases (11.7%) globally, followed by lung cancers (11.4%), colorectal cases (10.0%), prostate (7.3%), and stomach (5.6%) cancers. The global cancer burden has been estimated to increase by 47% in 2040, reaching up-to 28.4million cases globally.The comprehensive study of the global solid tumor testing market by BIS Research covers the following:• Market numbers on micro-segments that are influencing the market• More than 300 products present in the market. • Market share analysis for more than 15 companies• End-user preference data for over 20 end users• Detailed global and regional market share analysis, including the scrutiny of more than 15 countries.? • Study of data of more than 30 companiesWho should buy this Report?• Manufacturers of sequencing instruments, kits, assays, and consumables• Manufacturers of imaging instruments, kits, assays, and consumables• Companies involved in drug manufacturing and diagnostics development• Companies in the services market such as contract research organizationTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include end user and market share analysis, growth share analysis, global cancer epidemic data, cancer type, technology, application, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, including the high scope for adoption of genomic-based medicine in emerging nations, rising cancer incidence, increasing adoption of inorganic growth strategies, and decreasing cost of sequencing.The end user and product analysis of the global market includes data analysis on the satisfaction level of different kits and assays and services offered by the leading and emerging companies. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as consumables and services. The consumables are further categorized into kits and reagents. To emphasize the dominance of the clinical segment over the research segment under the product category of solid tumor testing market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst, BIS Research, states, "The reason for market growth can be attributed to the large-scale research and development and piqued interest of the clinicians in implementing personalized medicine offering rapid and biomarker driven results. Moreover, an increase in the product approvals and launch has led to the availability of an array of novel assays for prognosis and diagnosis of solid tumors, which has consequently increased clinical applications of the solid tumor testing services.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 17 leading companies, market participants, and vendors. The key players profiled in the report include Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.How can market intelligence on solid tumor testing add value to an organization’s decision-making process?• Aid in development • Help in targeting a segment for launching a new product • Offer detailed information on the future perspective of the emerging as well as established players• Offer go-to-market strategies for the different source type• Support in diversifying the product portfolio based on risk and progression of technology (ISH, NGS, PCR, and others)• Help in analyzing technological substitutes and compare the specifications• Offer tailor-made solutions based on the throughput of different consumers• Aid in understanding the technology requirement• Assist in exploring the newer application• Support in analyzing the competitors’ funding scenario• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)• Aid in understanding the new trends in the industryInsightful Questions Covered to Enable Companies take Strategic Decisions• What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global solid tumor testing market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period 2020 to 2030 based on the following segments? o cancer type o technology o application o end user o region • Which are the leading players with significant offerings to the global solid tumor testing market? • What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?
Companies Mentioned :
ARUP LaboratoriesASURAGEN, INC.Bio-Rad Laboratories, Inc.Beijing Genomics Institute (BGI) Genomics Co., LtdF. Hoffmann-La Roche Ltd.Guardant HealthIllumina, Inc.Invivoscribe, Inc.Invitae CorporationLaboratory Corporation of America HoldingsNeoGenomics Laboratories, Inc.Opko HealthOmniSeqQIAGEN N.V.Quest Diagnostics Incorporated
Press Release :
The premium market intelligence report published by BIS Research on the title Global Solid Tumor Testing Market highlights that the market is projected to reach $40.6 billion by 2030. The study also highlights that the market is set to witness a CAGR of 6.09% during the period 2020-2030. The growth of the market is aided by rising government initiatives for the implementation of precision medicine coupled with the increasing incidence of cancers globally.Solid tumors are defined as abnormal cellular growth in various organs, referred to as sarcomas, carcinomas, and lymphomas. The global cancer burden has been growing exponentially, specifically in countries with medium and low health development indexes. In 2020, breast cancer had the highest incidence of 2.3 million new cancer cases (11.7%) globally, followed by lung cancers (11.4%), colorectal cases (10.0%), prostate (7.3%), and stomach (5.6%) cancers. The global cancer burden has been estimated to increase by 47% in 2040, reaching up-to 28.4million cases globally.The comprehensive study of the global solid tumor testing market by BIS Research covers the following:• Market numbers on micro-segments that are influencing the market• More than 300 products present in the market. • Market share analysis for more than 15 companies• End-user preference data for over 20 end users• Detailed global and regional market share analysis, including the scrutiny of more than 15 countries.? • Study of data of more than 30 companiesWho should buy this Report?• Manufacturers of sequencing instruments, kits, assays, and consumables• Manufacturers of imaging instruments, kits, assays, and consumables• Companies involved in drug manufacturing and diagnostics development• Companies in the services market such as contract research organizationTo gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include end user and market share analysis, growth share analysis, global cancer epidemic data, cancer type, technology, application, end user, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, including the high scope for adoption of genomic-based medicine in emerging nations, rising cancer incidence, increasing adoption of inorganic growth strategies, and decreasing cost of sequencing.The end user and product analysis of the global market includes data analysis on the satisfaction level of different kits and assays and services offered by the leading and emerging companies. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as consumables and services. The consumables are further categorized into kits and reagents. To emphasize the dominance of the clinical segment over the research segment under the product category of solid tumor testing market in 2020 and 2030, Nitish Kumar Singh, Principal Analyst, BIS Research, states, "The reason for market growth can be attributed to the large-scale research and development and piqued interest of the clinicians in implementing personalized medicine offering rapid and biomarker driven results. Moreover, an increase in the product approvals and launch has led to the availability of an array of novel assays for prognosis and diagnosis of solid tumors, which has consequently increased clinical applications of the solid tumor testing services.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 17 leading companies, market participants, and vendors. The key players profiled in the report include Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Beijing Genomics Institute (BGI), QIAGEN N.V., ASURAGEN, INC., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., Invivoscribe, Inc., Inviate Corporation, Opko Health, Laboratory Corporation of American Holdings, OmniSeq, and Guardant Health.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.How can market intelligence on solid tumor testing add value to an organization’s decision-making process?• Aid in development • Help in targeting a segment for launching a new product • Offer detailed information on the future perspective of the emerging as well as established players• Offer go-to-market strategies for the different source type• Support in diversifying the product portfolio based on risk and progression of technology (ISH, NGS, PCR, and others)• Help in analyzing technological substitutes and compare the specifications• Offer tailor-made solutions based on the throughput of different consumers• Aid in understanding the technology requirement• Assist in exploring the newer application• Support in analyzing the competitors’ funding scenario• Support in understanding the involvement of government health organizations such as the National Institute of Health (NIH)• Aid in understanding the new trends in the industryInsightful Questions Covered to Enable Companies take Strategic Decisions• What are the major market drivers, challenges, and opportunities in the global solid tumor testing market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global solid tumor testing market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period 2020 to 2030 based on the following segments? o cancer type o technology o application o end user o region • Which are the leading players with significant offerings to the global solid tumor testing market? • What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global solid tumor testing market?
Headline :
Global Solid Tumor Testing Market to Reach $40.6 Billion by 2030
Table of Contents :
Executive Summary 1 Product Definition1.1 Inclusion and Exclusion2 Market Scope2.1 Scope of Work2.2 Key Questions Answered in the Report3 Research Methodology3.1 Global Solid Tumors Testing Market: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling4 Market Overview4.1 Definition4.2 Solid Tumor Testing Technologies4.3 Industry Participants Landscape4.4 Impact of COVID-19 on Delivery of Care for Cancer Patients5 Industry Insights5.1 Regulation of Genetic Tests5.1.1 FDA Regulation5.1.2 CMS Regulation5.2 Legal Requirements and Framework in Europe5.3 Legal Requirements and Framework in Asia-Pacific5.3.1 China5.3.2 Japan5.4 Reimbursement Scenario5.4.1 Impact on Laboratory Industry6 Market Dynamics6.1 Impact Analysis6.2 Market Drivers6.2.1 Rising Incidence of Cancers6.2.2 Decreasing Cost of Sequencing6.2.3 Increasing Adoption of Inorganic Growth Strategies in the Market6.2.4 Expected Increase in Adoption of Genetic Testing6.3 Market Restraints6.3.1 Uncertain Reimbursement Policies6.3.2 Requirement of High Capital Investment Hindering Expansion6.3.3 High Pricing Pressure6.4 Market Opportunities6.4.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations6.4.2 Technological Advancements in the Field of Cancer Genomics6.4.3 Mushrooming Direct-to-Consumer (DTC) Testing Services Market6.4.4 Increasing Disposable Income in Emerging Economies7 Competitive Landscape7.1 Key Strategies and Developments7.1.1 Synergistic Activities7.1.2 Approvals7.1.3 Product Launches, Enhancements, and Expansions7.1.4 Acquisitions and Mergers7.2 Product Scenario7.3 Market Share Analysis7.4 Growth-Share Analysis (Opportunity Mapping)7.4.1 By Company7.4.2 By Technology7.4.3 By Application7.4.4 By Cancer Type8 Global Solid Tumor Testing Market (by Technology), $Million, 2019-20308.1 Overview8.2 Next-Generation Sequencing8.3 In Situ Hybridization8.4 Polymerase Chain Reaction8.5 Immunohistochemistry8.6 Other Technologies9 Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-20309.1 Overview9.2 Breast Cancer9.3 Prostate Cancer9.4 Colorectal Cancer9.5 Lung Cancer9.6 Melanoma9.7 Endometrial Cancer9.8 Thyroid Cancer9.9 Brain Cancer9.1 Ovarian Cancer9.11 Liver Cancer9.12 Other Cancer Types10 Global Solid Tumor Testing Market, by Application, $Million, 2019-203010.1 Overview10.2 Clinical10.3 Research11 Global Solid Tumor Testing Market (by Region), $Million, 2019-203011.1 Overview11.2 North America11.2.1 U.S.11.2.2 Canada11.3 Europe11.3.1 Germany11.3.2 U.K.11.3.3 France11.3.4 Italy11.3.5 Spain11.3.6 Rest-of-Europe11.4 Asia-Pacific11.4.1 China11.4.2 Japan11.4.3 India11.4.4 Singapore11.4.5 Australia11.4.6 Rest-of-APAC11.5 Latin America11.5.1 Brazil11.5.2 Mexico11.5.3 Rest-of-LATAM11.6 Rest-of-the-World (RoW)12 Global Solid Tumor Testing Market, by End User, $Million, 2019-203012.1 Overview12.2 Hospitals, Diagnostic Laboratories, and Reference Laboratories12.3 Pharmaceutical and Biotechnology Companies12.4 Contract Research Organizations12.5 Academic Research Institutions12.6 Other End Users13 Company Profiles13.1 Overview13.2 Abbott Laboratories13.2.1 Company Overview13.2.2 Role of Abbott Laboratories in the Global Solid Tumor Testing Market13.2.3 Financials13.2.4 Key Insights About Financial Health of the Company13.2.5 SWOT Analysis13.3 ARUP Laboratories13.3.1 Company Overview13.3.2 Role of ARUP Laboratories in the Global Solid Tumor Testing Market13.3.3 SWOT Analysis13.4 ASURAGEN, INC.13.4.1 Company Overview13.4.2 Role of ASURAGEN, INC. in the Global Solid Tumor Testing Market13.4.3 SWOT Analysis13.5 Bio-Rad Laboratories, Inc.13.5.1 Company Overview13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global Solid Tumor Testing Market13.5.3 Financials13.5.4 Key Insights About Financial Health of the Company13.5.5 SWOT Analysis13.6 Beijing Genomics Institute (BGI) Genomics Co., Ltd13.6.1 Company Overview13.6.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the Global Solid Tumor Testing Market13.6.3 SWOT Analysis13.7 F. Hoffmann-La Roche Ltd.13.7.1 Company Overview13.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Solid Tumor Testing Market13.7.3 Financials13.7.4 Key Insights About Financial Health of the Company13.7.5 SWOT Analysis13.8 Guardant Health13.8.1 Company Overview13.8.2 Role of Guardant Health in the Global Solid Tumor Testing Market13.8.3 Financials13.8.4 SWOT Analysis13.9 Illumina, Inc.13.9.1 Company Overview13.9.2 Role of Illumina, Inc. in the Global Solid Tumor Testing Market13.9.3 Financials13.9.4 Key Insights About Financial Health of the Company13.9.5 SWOT Analysis13.1 Invivoscribe, Inc.13.10.1 Company Overview13.10.2 Role of Invivoscribe, Inc. in the Global Solid Tumor Testing Market13.10.3 SWOT Analysis13.11 Invitae Corporation13.11.1 Company Overview13.11.2 Role of Invitae Corporation, Inc. in the Global Solid Tumor Testing Market13.11.3 Financials13.11.4 Key Insights About Financial Health of the Company13.11.5 SWOT Analysis13.12 Laboratory Corporation of America Holdings13.12.1 Company Overview13.12.2 Role of Laboratory Corporation of America Holdings in the Global Solid Tumor Testing Market13.12.3 Financials13.12.4 SWOT Analysis13.13 NeoGenomics Laboratories, Inc.13.13.1 Company Overview13.13.2 Role of NeoGenomics Laboratories, Inc. in the Global Solid Tumor Testing Market13.13.3 Financials13.13.4 Key Insights About Financial Health of the Company13.13.5 SWOT Analysis13.14 Opko Health13.14.1 Company Overview13.14.2 Role of Opko Health, Inc. in the Global Solid Tumor Testing Market13.14.3 Financials13.14.4 Key Insights About Financial Health of the Company13.14.5 SWOT Analysis13.15 OmniSeq13.15.1 Company Overview13.15.2 Role of OmniSeq in the Global Solid Tumor Testing Market13.15.3 SWOT Analysis13.16 QIAGEN N.V.13.16.1 Company Overview13.16.2 Role of QIAGEN N.V. in the Global Solid Tumor Testing Market13.16.3 Financials13.16.4 Key Insights About Financial Health of the Company13.16.5 SWOT Analysis13.17 Quest Diagnostics Incorporated13.17.1 Company Overview13.17.2 Role of Quest Diagnostics Limited in the Global Solid Tumor Testing Market13.17.3 Financials13.17.4 SWOT AnalysisList of Figures Figure 1: Global Cancer Incidence and Prevalence, Cancer Types, 2020Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Solid Tumor Testing MarketFigure 3: Global Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030Figure 4: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2020 and 2030Figure 5: Global Solid Tumor Testing Market (by Application), $Million, 2020 and 2030Figure 6: Global Solid Tumor Testing Market (by End User), $Million, 2020 and 2030Figure 2.1: Global Solid Tumor Testing Market SegmentationFigure 3.1: Global Solid Tumor Testing Market Research MethodologyFigure 6.1: Cancer Cases Projections, 2015-2020Figure 6.2: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)Figure 6.3: Synergistic Activities, 2017-2019Figure 6.4: SBIR and STTR Grants and Contract Funding, 2008-2018Figure 6.5: NCI Fiscal Budget Year on Year, 2013-2018Figure 7.1: Share of Key Strategies and Developments, January 2017-March 2021Figure 7.2: Synergistic Activities Share (by Company), January 2017-March 2021Figure 7.3: Approvals Share (by Company), January 2017-March 2021Figure 7.4: Product Launches, Enhancements and Expansions Share (by Company), January 2017-March 2021Figure 7.5: Acquisitions and Mergers Share (by Company), January 2017-March 2021Figure 7.6: Market Share Analysis for the Global Solid Tumor Testing Market, 2020Figure 7.7: Growth-Share Matrix for Global Solid Tumor Testing Market (by Company), 2020Figure 7.8: Growth Share Matrix for Global Solid Tumor Testing Market (by Technology), 2020Figure 7.9: Growth-Share Matrix for Global Solid Tumor Testing Market (by Application), 2020Figure 7.10: Growth-Share Matrix for Global Solid Tumor Testing Market (by Cancer Type), 2020Figure 8.1: Global Solid Tumor Testing Market (by Technology), $Million, 2019-2030Figure 8.2: Global Solid Tumor Testing Market (NGS), $Million, 2019-2030Figure 8.3: Global Solid Tumor Testing Market (ISH), $Million, 2019-2030Figure 8.4: Global Solid Tumor Testing Market (for PCR), $Million, 2019-2030Figure 8.5: Global Solid Tumor Testing Market (IHC), $Million, 2019-2030Figure 8.6: Global Solid Tumor Testing Market (Other Technologies), $Million, 2019-20230Figure 9.1: Global Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030Figure 9.2: Global Cancer Incidence, 2020Figure 9.3: Global Solid Tumor Testing Market (Breast Cancer), $Million, 2019-2030Figure 9.4: Global Cancer Incidence, 2020Figure 9.5: Global Solid Tumor Testing Market (for Prostate Cancer), $Million, 2019-2030Figure 9.6: Global Cancer Incidence, 2020Figure 9.7: Global Solid Tumor Testing Market (Colorectal Cancer), $Million, 2019-2030Figure 9.8: Global Cancer Incidence, 2020Figure 9.9: Global Solid Tumor Testing Market (for Lung Cancer), $Million, 2019-2030Figure 9.10: Global Cancer Incidence, 2020Figure 9.11: Global Solid Tumor Testing Market (Melanoma), $Million, 2019-2030Figure 9.12: Global Cancer Incidence, 2020Figure 9.13: Global Solid Tumor Testing Market (Endometrial Cancer), $Million, 2019-2030Figure 9.14: Global Cancer Incidence, 2020Figure 9.15: Global Solid Tumor Testing Market (for Thyroid Cancer), $Million, 2019-2030Figure 9.16: Global Cancer Incidence, 2020Figure 9.17: Global Solid Tumor Testing Market (Brain Cancer), $Million, 2019-2030Figure 9.18: Global Cancer Incidence, 2020Figure 9.19: Global Solid Tumor Testing Market (Ovarian Cancer), $Million, 2019-2030Figure 9.20: Global Cancer Incidence, 2020Figure 9.21: Global Solid Tumor Testing Market (for Liver Cancer), $Million, 2019-2030Figure 9.22: Global Solid Tumor Testing Market (for Other Cancer Types), $Million, 2019-2030Figure 10.1: Global Solid Tumor Testing Market (by Application), $Million, 2019-2030Figure 10.2: Global Solid Tumor Testing Market (by Clinical Applications), $Million, 2019-2030Figure 10.3: Global Solid Tumor Testing Market (Research Applications), $Million, 2019-2030Figure 10.4: Global Solid Tumor Testing Market (by Research Applications), $Million, 2019-2030Figure 11.1: Global Solid Tumor Testing Market (by Region), $Million, 2020 and 2030Figure 11.2: Global Solid Tumor Testing Market (by Region), $Million, 2019-2030Figure 11.3: North America Solid Tumor Testing Market, $Million, 2019-2030Figure 11.4: North America Solid Tumor Testing Market (by Country), $Million, 2019-2030Figure 11.5: North America: Market DynamicsFigure 11.6: U.S. Solid Tumor Testing Market, $Million, 2019-2030Figure 11.7: Canada Solid Tumor Testing Market, $Million, 2019-2030Figure 11.8: Total Market Size for North America Solid Tumor Testing Market (by Technology), 2020 and 2030Figure 11.9: Total Market Size for North America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030Figure 11.10: Europe: Market DynamicsFigure 11.11: Europe Solid Tumor Testing Market, $Million, 2019-2030Figure 11.12: Europe Solid Tumor Testing Market (by Country), $Million, 2019-2030Figure 11.13: Germany Solid Tumor Testing Market, $Million, 2019-2030Figure 11.14: U.K. Solid Tumor Testing Market, $Million, 2019-2030Figure 11.15: France Solid Tumor Testing Market, $Million, 2019-2030Figure 11.16: Italy Solid Tumor Testing Market, $Million, 2019-2030Figure 11.17: Spain Solid Tumor Testing Market, $Million, 2019-2030Figure 11.18: Rest-of-Europe (RoE) Solid Tumor Testing Market, $Million, 2019-2030Figure 11.19: Total Market Size for Europe Solid Tumor Testing Market (by Technology), 2020 and 2030Figure 11.20: Total Market Size for Europe Solid Tumor Testing Market (by Cancer Type), $Million, 2019-2030Figure 11.21: Asia-Pacific Solid Tumor Testing Market, $Million, 2019-2030Figure 11.22: APAC: Market DynamicsFigure 11.23: Asia-Pacific Solid Tumor Testing Market (by Country), $Million, 2019-2030Figure 11.24: China Solid Tumor Testing Market, $Million, 2019-2030Figure 11.25: Japan Solid Tumor Testing Market, $Million, 2019-2030Figure 11.26: India Solid Tumor Testing Market, $Million, 2019-2030Figure 11.27: Singapore Solid Tumor Testing Market, $Million, 2019-2030Figure 11.28: Australia Solid Tumor Testing Market, $Million, 2019-2030Figure 11.29: Rest-of-APAC Solid Tumor Testing Market, $Million, 2019-2030Figure 11.30: Total Market Size for Asia-Pacific Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030Figure 11.31: Total Market Size for Asia Pacific Solid Tumor Testing Market (by Cancer), $Million, 2019-2030Figure 11.32: Latin America Solid Tumor Testing Market, $Million, 2019-2030Figure 11.33: Latin America: Market DynamicsFigure 11.34: Latin America Solid Tumor Testing Market (by Country), $Million, 2019-2030Figure 11.35: Brazil Solid Tumor Testing Market, $Million, 2019-2030Figure 11.36: Mexico Solid Tumor Testing Market, $Million, 2019-2030Figure 11.37: Rest-of-LATAM Solid Tumor Testing Market, $Million, 2019-2030Figure 11.38: Total Market Size for Latin America Solid Tumor Testing Market (by Technology), $Million, 2020 and 2030Figure 11.39: Total Market Size for Latin America Solid Tumor Testing Market (by Cancer), $Million, 2019-2030Figure 11.40: RoW Solid Tumor Testing Market, $Million, 2019-2030Figure 12.1: Global Solid Tumor Testing Market (by End User), $Million, 2019-2030Figure 12.2: Global Solid Tumor Testing Market (Hospitals, Diagnostic Laboratories, and Reference Laboratories), $Million, 2019-2030Figure 12.3: Global Solid Tumor Testing Market (Pharmaceutical and Biotechnology Companies), $Million, 2019-2030Figure 12.4: Global Solid Tumor Testing Market (Contract Research Organization), $Million, 2019-2030Figure 12.5: Global Solid Tumor Testing Market (Academic Research Institutions), $Million, 2019-2030Figure 12.6: Global Solid Tumor Testing Market (Other End Users), $Million, 2019-2030Figure 13.1: Total Number of Companies ProfiledFigure 13.2: Abbott Laboratories: PortfolioFigure 13.3: Abbott Laboratories: Overall Financials, 2018-2020Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2018-2020Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2018-2020Figure 13.6: Abbott Laboratories: Revenue (by Region), 2018-2020Figure 13.7: Abbott Laboratories: R&D Expenditure, 2018-2020Figure 13.8: Abbott Laboratories: SWOT AnalysisFigure 13.9: ARUP Laboratories: PortfolioFigure 13.10: ARUP Laboratories: SWOT AnalysisFigure 13.11: ASURAGEN, INC.: PortfolioFigure 13.12: ASURAGEN, INC.: SWOT AnalysisFigure 13.13: Bio-Rad Laboratories, Inc.: PortfolioFigure 13.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019Figure 13.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019Figure 13.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019Figure 13.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019Figure 13.18: Bio-Rad Laboratories, Inc.: SWOT AnalysisFigure 13.19: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Product PortfolioFigure 13.20: Beijing Genomics Institute (BGI) Genomics Co., Ltd.: SWOT AnalysisFigure 13.21: F. Hoffmann-La Roche Ltd: PortfolioFigure 13.22: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020Figure 13.23: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2018-2020Figure 13.24: F. Hoffmann-La Roche Ltd: Sales (by Region), 2018-2020Figure 13.25: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020Figure 13.26: F. Hoffmann-La Roche: SWOT AnalysisFigure 13.27: Guardant Health: PortfolioFigure 13.28: Guardant Health: Overall Financials, $Million, 2017-2019Figure 13.29: Guardant Health: Revenue (by Segment), $Million, 2017-2019Figure 13.30: Guardant Health: Revenue (by Region), $Million, 2017-2019Figure 13.31: Guardant Health: SWOT AnalysisFigure 13.32: Illumina, Inc.: PortfolioFigure 13.33: Illumina, Inc.: Overall Financials, 2018-2020Figure 13.34: Illumina, Inc.: Revenue (by Segment), 2017-2020Figure 13.35: Illumina, Inc.: Revenue (by Region), 2018-2020Figure 13.36: Illumina, Inc.: R&D Expenditure, 2018-2020Figure 13.37: Illumina, Inc.: SWOT AnalysisFigure 13.38: Invivoscribe, Inc.: PortfolioFigure 13.39: Invivoscribe, Inc.: SWOT AnalysisFigure 13.40: Invitae Corporation: PortfolioFigure 13.41: Invitae Corporation: Overall Financials, 2018-2020Figure 13.42: Invitae Corporation: Revenue (by Segment), 2018-2020Figure 13.43: Invitae Corporation: Revenue (by Geography), 2018-2020Figure 13.44: Invitae Corporation: R&D Expenditure, 2018-2020Figure 13.45: Invitae Corporation: SWOT AnalysisFigure 13.46: Laboratory Corporation of America Holdings: PortfolioFigure 13.47: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020Figure 13.48: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020Figure 13.49: Laboratory Corporation of America Holdings: SWOT AnalysisFigure 13.50: NeoGenomics Laboratories, Inc.: PortfolioFigure 13.51: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020Figure 13.52: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020Figure 13.53: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020Figure 13.54: NeoGenomics Laboratories, Inc.: SWOT AnalysisFigure 13.55: Opko Health: PortfolioFigure 13.56: Opko Health: Overall Financials, 2018-2020Figure 13.57: Opko Health: Revenue (by Segment), 2018-2020Figure 13.58: Opko Health: Revenue (by Region), 2018-2020Figure 13.59: Opko Health: R&D Expenditure, 2018-2020Figure 13.60: Opko Health: SWOT AnalysisFigure 13.61: OmniSeq: PortfolioFigure 13.62: OmniSeq: SWOT AnalysisFigure 13.63: QIAGEN N.V.: PortfolioFigure 13.64: QIAGEN N.V.: Overall Financials, 2017-2019Figure 13.65: QIAGEN N.V.: Revenue (by Segment), 2017-2019Figure 13.66: QIAGEN N.V.: Revenue (by Region), 2017-2019Figure 13.67: QIAGEN N.V.: R&D Expenditure, 2017-2019Figure 13.68: QIAGEN N.V.: SWOT AnalysisFigure 13.69: Quest Diagnostics Incorporated: PortfolioFigure 13.70: Quest Diagnostics Incorporated: Overall Financials, 2017-2019Figure 13.71: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019Figure 13.72: Quest Diagnostics Incorporated: SWOT AnalysisList of Tables Table 4.1: Solid Tumor Testing Technologies for Clinical LaboratoriesTable 4.2: Technological Trends in Solid Tumor Testing MarketTable 4.3: Industry Participants Landscape in the Global Solid Tumor Testing MarketTable 5.1: Examples of New CPT Codes Under the CMSTable 5.2: New Payment Amounts for ADLTsTable 6.1: Likert ScaleTable 6.2: Impact Analysis of Market DriversTable 6.3: Impact Analysis of Market RestraintsTable 7.1: Market Players with Key Product Listing